A peptide derived from alpha-fetoprotein inhibits the proliferation induced by estradiol in mammary tumor cells in culture

WALTER D. SIERRALTA1, MARIA J. EPUÑAN1, JOSÉ M. REYES3, LUIS E. VALLADARES2, THOMAS T. ANDERSEN4, JAMES A. BENNETT4, HERBERT I. JACOBSON4 and ANA M. PINO1

Laboratorios de 1Ultrastructuras and 2Hormonas y Receptores, INTA-Universidad de Chile, Avda. Macul 5540, Santiago 7830489; 3Centro de Oncología, Clínica Las Condes, Lo Fontecilla 454, Las Condes, Chile; 4Center for Cardiovascular Sciences and Department of Obstetrics, Gynecology and Reproductive Sciences, Albany Medical College MC-16, 47 New Scotland Ave, Albany, NY 12208, USA

Received May 29, 2007; Accepted July 25, 2007

Abstract. This study was aimed to obtain additional information on the activity of a cyclized 9-amino acid peptide (cP) containing the active site of alpha fetoprotein, which inhibits the estrogen-stimulated proliferation of tumor cells in culture and of xenografts in immunodeficient mice. Breast cancer cells cultured in the presence of 2 nM estradiol were exposed to cP for different periods and their proliferation, estradiol binding parameters, clustering tendency and expression of E-cadherin and p21Cip1 were analyzed by biochemical and cell biology methods. The proliferation of MCF7 cells was significantly decreased by the addition of 2 μg/ml cP to the medium. cP did not increase cell death rate nor alter the number of binding sites for estradiol nor the endogenous aromatase activity of MCF7 cells. cP also decreased the proliferation of estrogen-dependent ZR75-1 cells but had no effect on estrogen-independent MDA-MB-231 cells. An increased nuclear p21Cip1 expression detected after cP treatment suggests that cP slows MCF7 cell proliferation via this regulator. We propose that cP could represent a novel breast cancer therapeutic agent whose mechanism of action is different from that of tamoxifen or of inhibitors of aromatase.

Introduction

The most common cancer in women worldwide affects the mammary gland, a tissue composed of highly-sensitive target cells for estradiol that contain the estradiol receptors α and β (ERα, ERβ) (1). These receptors bind to estrogen-response elements in the promoter region of cognate target genes, or interact with proteins in other pathways to regulate the transcription of specific genes in estrogen-dependent cells (2-6). Estradiol has a proliferative effect on breast cancer cells, regulating the biosynthesis of some growth factors (7-9), of growth factor receptors and of other signaling molecules (10). In addition, estradiol can activate phosphatidylinositol-3-kinase and mitogen-activated protein kinase pathways (11-13).

Several studies indicate that estrogen action can induce and promote breast cancer; therefore, decreasing estrogen production by aromatase inhibitors or blocking its action with antiestrogens have been the main treatments for ERα-positive tumors (14,15).

Little is known about the physiological role of alpha-fetoprotein (AFP), a glycoprotein produced mainly by the fetal liver (16) and thought to play a protecting role for the offspring during fetal and perinatal development. Recent studies in mice demonstrate that AFP prevents entry of estrogens in developing brain, facilitating the normal development of the female fetal brain (17). From epidemiologic studies on pregnancy-associated protection against breast cancer, Jacobson et al hypothesized that AFP acts in an endocrine manner to extinguish premalignant foci in pregnant women (18). Jacobson et al also reported that AFP exerts antiestrogenic effects on breast cancer growth in rodent models (19) and, more recently, identified the active site of AFP responsible for this activity (20,21). The same investigators have synthesized a cyclized 9-mer AFP-active site analog, cyclo-EMTOVNOGQ (cP). This peptide remains very stable during long-term storage and, like AFP, has the ability to inhibit estradiol-stimulated growth of estrogen-dependent human breast cancer xenografts growing in severe combined immunodeficient (SCID) mice and to hinder the estrogen-stimulated growth of the uterus in immature animals (22). Furthermore, in vivo administration of the whole AFP molecule or the cP had no effect on estradiol circulating levels in rodents (22,23).
Much of what is known about the mitogenic actions of estrogen in ER-positive tumors has come from the study of hormone action in human breast cancer cells. Mammary tumor cells like wild-type MCF7, T47D and ZR75-1 proliferate faster when estradiol is present in the culture medium, evidencing their sensitivity towards the steroid. The simultaneous addition of an estradiol-interfering molecule to this system usually causes a reduction in the cell proliferation rate. Besides increased cell death rate, the most probable causes of reduced proliferation by the presence of a drug are specific alterations in the progress of the cell cycle, or a generalized slowing-down leading to cell senescence. Progression through the cell cycle is controlled by the coordinated activity of distinct cyclin-dependent kinases (CDKs) (24). CDKs are negatively regulated by two classes of CDK inhibitors (CKIs), namely the CIP/KIP and the INK4 families of proteins. Among the CIP/KIP proteins, p21Cip1 is considered a central regulator of the cell cycle (25). In addition, p21Cip1 participates in the control of other cell processes, regulated by a variety of stimuli including senescence, genome damage, serum starvation and differentiation (26).

The aim of this study was to study the inhibitory effect of cP on growth of mammary tumor cells in culture. We report the effect of the AFP-derived cyclic peptide on the proliferation, clustering tendency and p21Cip1 expression of MCF7 cells cultured in the presence and absence of estradiol.

Materials and methods

Materials. The AFP-derived nonapeptide cyclo (EKTOV-NOGN) (where O is hydroxyproline) and a control scrambled peptide were obtained by solid-phase peptide synthesis using N-(9-fluorenyl)methoxycarbonyl, as already described (22). Tissue culture materials, PVDF membranes and precision Plus Protein Standards were purchased from NalgeNunc (Rochester, NY, USA) and BioRad Laboratories (Hercules, CA, USA), respectively. 2,4,6,7-tritium labeled estradiol was purchased from NEN Life Science Division of Perkin-Elmer (Boston, MA, USA). The following antibodies were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) anti-E-cadherin murine monoclonal antibody (sc8426); anti-p21Cip1 rabbit polyclonal antibody (sc756) and FITC-conjugated goat anti-mouse IgG (sc2010). AlexaFluor-488 conjugated donkey anti-rabbit IgG (A21206) was purchased from Molecular Probes-Invitrogen Corp. (Carlsbad, CA, USA).

Cell lines. Estradiol-sensitive MCF7 epithelial cells established from human metastatic breast cancer tissue (HTB 22; ATCC, USA), were cultured in MEM-Eagle media containing 10% calf serum, 1 mM sodium pyruvate, 2 mM L-glutamine and antibiotics. The estradiol-sensitive human breast carcinoma cell line ZR75-1 (CRL 1500; ATCC, USA), was cultured in RPMI-1640 medium adjusted to 2 mM L-glutamine, 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 10 mM HEPES, and 1 mM sodium pyruvate and containing 10% calf serum and antibiotics. Charcoal dextran-stripped calf serum (CDSs) was used in all cases, to reduce the content of endogenous estradiol in calf serum (27); calf serum was used to avoid the presence of alpha fetoprotein. Cells were incubated at 37°C in a humidified incubator, in a 5% CO2 atmosphere.

Proliferation studies. MCF7 (12,000 cells/cm²), ZR75-1 (16,000 cells/cm²), and MDA-MB231 (6,000 cells/cm²), were seeded and incubated for 24 h. After cells became attached to the culture vessel, non-adherent cells and media were removed. The adherent cells were reincubated with the respective culture medium containing either 2 nM estradiol or 2 μg/ml of cyclic peptide for various periods of time, with a change of culture medium every 48 h. For all cell lines, parallel control experiments in the absence of estradiol or cyclic peptide or in the presence of a scrambled peptide were performed. All experiments were done in triplicate.

At the completion of the incubation period, cells were washed with phosphate-buffered saline (PBS), detached (0.25% trypsin in 0.2 mM EDTA), resuspended in PBS, counted and assessed for viability (trypan blue).

Doubling time measurements. Doubling times were determined from growth curves of MCF7 cells inoculated at t₀ at a density of 10,000 cells/cm². Cell counts were measured in triplicate in a haemocytometer every 24 h for up to 120 h. The counts were plotted on a log scale and fitted to a straight line by linear regression.

Cell cycle studies. For these studies, MCF7 cells (10,000 cells/cm²) were seeded in B25 bottles; once attached the cells were serum deprived for 24 h. Synchronized cells were then incubated with culture medium containing 2 nM estradiol with or without 2 μg/ml of the cyclic peptide. At defined time periods, cell aliquots were labeled with propidium iodide (PI, 10 mg/ml), treated with RNase A (300 μg/ml) and their DNA content analyzed by the ModFit LTTM software (Becton-Dickinson, CA, USA) using a FACScaliber (Becton-Dickinson).

Immunofluorescence studies. Cells exposed to different experimental conditions were grown on sterile coverglass and then fixed (methanol, 20 min at -20°C), rinsed (PBS containing 2% BSA), and their DNA content analyzed by the ModFit LTTM software (Becton-Dickinson, CA, USA) using a FACScaliber (Becton-Dickinson).

Western blot analysis. For total cell protein extraction, cells were sonicated in RIPA buffer (0.5% deoxycholate, 1% SDS, 1% nonidet NP-40, 150 mM NaCl, 50 mM Tris, pH 8.0) containing PMSF (phenylmethylsulfonylfluoride) and complete protease inhibitor cocktail. For SDS/PAGE, 40 μg protein samples were incubated for 5 min at 95°C and loaded in 10% polyacrylamide gels. Electrophoresis was performed at RT for 1 h at 100 V using BioRad Miniprotein chambers.
Bands were electro-transferred onto PVDF membranes and immunodetection was done by using the appropriate primary antibodies and peroxidase-labelled secondary antibodies. Bands were developed with DAB and hydrogen peroxide.

Statistical analyses. Student's t-test was used to evaluate differences between samples and the respective controls; p<0.05 was considered significant. Data were analyzed with Statistica for Windows Software, release 6, Statsoft Inc., USA.

Results

Effect of the cyclized peptide (cP) on the proliferation of mammary tumor cells. The effect of the cP on the proliferation rate of two estradiol-sensitive epithelial cell lines (MCF7 and ZR75-1) and the estradiol-insensitive cell line MDA-MB231, was studied at various conditions as indicated in Fig. 1.

Proliferation of the estradiol-dependent cell line MCF7 was inhibited after cP addition in the culture media, observing the maximal inhibitory effect (~40%) after 6 days (Fig. 1A). In addition, the inhibitory effect of cP was structure-dependent since the addition of a scrambled peptide (2 μg/ml) did not affect estrogen-dependent growth of these cells (Fig. 1A, day 6). The inhibitory effect of cP on MCF7 proliferation was dose-dependent and attained a maximum at 2 μg/ml cP concentration (Fig. 1B). The effect was reversible since although a lag of 48 h followed after cP withdrawal from the medium, proliferation rate recovered allowing to come close to the cell number obtained under 2 nM estradiol (Fig. 1C). Inhibition...
of proliferation by cP seems to be specific for the growth of estradiol-dependent cells: like MCF7 cells, the proliferation of the estradiol-sensitive human breast cancer ZR75-1 cells was also inhibited by cP (Fig. 1D). Conversely, the growth of estradiol-insensitive MDA-MB231 cells was unaffected by the presence of cP in the culture medium (Fig. 1E).

The inhibitory effect of cP on MCF7 proliferation is disclosed by the values of cell doubling time measured in the absence or in the presence of cP (2 μg/ml), that increased from 52±2 to 63±3 h, respectively.

To assess whether the effect of cP on the estradiol-stimulated cell proliferation could be associated to a change in the transition of cells through the cell cycle, the percentage of cells at each stage of the cell cycle was assessed by flow cytometry. Results in Fig. 2 showed no change in the percentage of cells at each phase of the cycle when MCF7 cells were cultured with estradiol in the presence or absence of cP. In addition, under both conditions apoptotic cells were not detected, as shown by the lack of a sub-G0/G1 peak.

When MCF7 cells were seeded at mid cell density, cells grew as a mixture of large (≥20 cells) and small (<20 cells) clusters, tightly connected by strong cell-to-cell interactions (Fig. 3A). We investigated whether cP impaired cluster formation, analyzing the proportion of large and small cell clusters. We observed that the cP increased significantly the percentage of small clusters at the cost of the larger ones (Fig. 3B). Thus, the cP impaired the ability of MCF7 cells to grow and develop into large clusters.

Since growth of estradiol-sensitive breast cancer cells forming clusters and their aggressive behavior have been related to changes in E-cadherin expression (29), we analyzed E-cadherin expression by MCF7 cells grown both in the presence and absence of cP. As shown, no change in E-cadherin immunostaining by cells was observed (Fig. 3C, D). Western blotting confirmed that the level of E-cadherin expression by these cells is not affected by cP (Fig. 3E).

On the other hand, the estradiol-insensitive cell line MDA-MB231, which proliferates as single rather than clustered cells, was not affected by cP (data not shown).

Figure 2. Cell cycle analysis of MCF7 after stimulation with 2 nM estradiol in the presence or absence of 2 μg/ml cP. The results are presented as percentage of cells at each cell cycle stage. Means of 2 experiments ± range. Each time-point panel contains a FacSort representative graph depicting the distribution frequency of cells for each sample. Codes for the areas: M1, apoptosis; M2, G0/G1; M3, S; M4, G2/M.

Figure 3. Tendency of MCF7 cells to form clusters. (A), Representative images of MCF7 growth in clusters in the presence of 2 nM estradiol (left), and 2 nM estradiol and 2 μg/ml cP (right). The bar represents 100 μm. (B), Frequency of cluster sizes, after incubation MCF7 cells with 2 nM estradiol (grey bar) and with 2 nM estradiol plus 2 μg/ml cP (hatched bar). Representative fluorescence images of MCF7 cells grown for 16 h in medium containing 10% CDSS in the presence of 2 nM estradiol alone (C) or estradiol and 2 μg/ml cP (D). Content of E-cadherin in MCF7 cells grown under estradiol alone (E2) or plus cP (cPE2) is shown in the immunoblot (E).
Cellular and molecular mechanisms involved in the action of cP on the growth of estradiol-sensitive cells. The optimum growth of estradiol-sensitive epithelial cells in culture is known to depend on the concentration of estradiol and estradiol binding sites. Since estradiol could be bound unspecifically by cP reducing the hormone availability, we measured direct in vitro binding capacity by incubating several tritium labeled estradiol concentrations with different amounts of the cP. Using the hydroxyapatite assay (28), we found that the cP does not bind free estradiol. In addition, Scatchard analyses confirmed that the cP did not modify the association constant nor the number of estradiol-binding sites in MCF7 cells: in the presence and absence of cP, the value of Kd (0.073±0.002 nM) as well as the number of binding sites per cell (9,700±600) were maintained. 

It has been proposed that in situ-production of estrogens plays an important role in the promotion of breast tumors (30). Some human breast cancer cells have enhanced expression of the enzyme aromatase, allowing the production of estrogens from circulating androgens. Therefore, we studied whether the presence of cP during incubation hindered a putative generation of estrogens from androgens by MCF7 cells. Cell proliferation was measured without estradiol but in the presence or absence cP and androstenedione or testosterone as aromatase substrates. Results demonstrated that, independent of the presence of estradiol, cP did not significantly stimulate MCF7 cell proliferation. Furthermore, the propagation of these cells was not affected by addition of an aromatase inhibitor (data not shown).

Preclinical studies have shown that the treatment of breast cancer xenografts with cP induces the phosphorylation of p53, a major modulator of p21Cip1 (31). Therefore, we analyzed p21Cip1 immunostaining in MCF7 cells after exposure to cP (2 μg/ml) in the presence or absence of estradiol (2 nM). As shown in Fig. 4A, little localization of p21Cip1 was observed within the nuclei of estradiol-stimulated cells. In contrast, the simultaneous presence of cP and estradiol significantly increased the presence of p21Cip1 in nuclei (Fig. 4B). Moreover, in the absence of estradiol, cP caused increased p21Cip1 nuclear immunostaining (Fig. 4C). These observations are quantified and summarized in the Fig. 4D. The effect of the cP on p21Cip1 staining showed specific, since the scrambled peptide had no effect (data not shown).

Discussion

The effects of estrogens on target cells in culture are dependent on the experimental system employed (27). In our experiments, the proliferation of MCF7 cells increased 30-35% under 2 nM estradiol treatment in medium supplemented with CDSS, as compared to medium without the steroid. The addition of cP, but not that of a scrambled peptide, reduced the estrogen-stimulated growth of cells; the dose-response experiments showed that maximal effect was attained at 2 μg/ml cP (Fig. 1). This effect of cP was reversible, since removal of the peptide from the medium allowed cells to recover. The cP also inhibited the estrogen-dependent growth of ZR75-1 cells but had no effect on MDA-MB231, a known estrogen-unresponsive cell line (Fig. 1). These results complement recent observations on the effect of cP on the growth of mammary tumor cell xenografts in severely combined immunodeficient mice (22). Results also demonstrate that the cP did not
modify values of estradiol dissociation constant and number of binding sites in the MCF7 cells. Previous experiments have shown no interference of this peptide with estradiol binding to preparations enriched in estrogen receptor (23). Additionally, CP exhibited no effect on the endogenous generation of estradiol from androgens.

Comparisons of cell cycle progression between estradiol- and estradiol plus CP treated cells showed no apparent change in the percentage of cells at the G1, S and G2/M stages of the cell cycle. However, a significant reduction in the total number of cells was customarily observed. A similar situation in cell cycle progression (namely a transient multi-phase cell cycle arrest) has been reported in murine fibroblasts exposed to sub-lethal redox stress (32). FACSort analysis showed no change in the extent of cell apoptosis under CP and/or estradiol treatment and, in addition, light microscopy evaluation of fixed and hematoxylin-eosin-stained cells and immunoanalysis of active caspase 3 levels (data not shown) indicated that the presence of CP did not increase cell death. Thus, the reduced proliferation observed appears to be related with a generalized lengthening of the cell cycle. We conclude that the mechanism of action of CP is different from that of tamoxifen and other antiestrogens observed by Osborne et al. (33).

Differences in the size of the clusters formed after 16 h of exposure to CP and/or estradiol were observed, suggesting that the treatments could affect inter-cell attraction. It has been reported that in MCF7 cells growing as clusters, a decrease of E-cadherin expression accompanies the loss of cellular contacts and seems to be associated with a diminished cell proliferation without the participation of apoptosis (34). Therefore we analyzed, by immunofluorescence and immunoblotting, the effect of CP on E-cadherin and found that the cyclic peptide did not induce changes in the expression of this protein, ruling out an effect of CP on this pathway of intercellular adhesion.

The protein p21Cip1 controls the cell cycle, sustained high levels of this inhibitor for prolonged time arrests growth of epithelial cells (35). In addition, other functions for p21Cip1 have been demonstrated, including regulation of transcription, protection from apoptosis and modulation of cell motility (25,36), among others. Therefore, modulation of p21Cip1 expression or its function might be fundamental for regulation of the proliferative activity. In cultured mammary tumor cells, p21Cip1 is activated by both p53-dependent and independent mechanisms, and behaves as an estrogen-modulated protein (37). The low levels of p21Cip1 in wild-type MCF7 cells limited a quantitative assessment of p21 by immunoblotting (38). For this reason we used the sensitive but qualitative immunofluorescence analysis, that showed that CP affected nuclear p21Cip1 immunoreactivity of MCF7 cells depending on the presence or absence of estradiol. Cells exposed to estradiol showed low number of p21Cip1 immunostained nuclei. In cells treated with CP alone, the number of p21Cip1 stained nuclei increased significantly; but this effect was diminished when estradiol was also present in the medium. Our results show that CP promotes nuclear accumulation of p21Cip1 which could slow down cell proliferation. This observation supports results showing that CP hinders estrogen-stimulated growth of human breast cancer xenografts (31). We conclude that CP could transiently remove an estradiol-dependent block on p21Cip1 expression, thus reducing the proliferative estradiol effect on MCF7 cells (39); alternatively, CP treatment might increase p21Cip1 gene expression. In any case, high levels of p21Cip1 would extend the proliferation time of MCF7 cells. Further studies are required to clarify these alternatives.

Summarizing, our results show that CP interferes with the estradiol-dependent proliferation of mammary cancer cells; the presence of CP increased nuclear p21Cip1 immunoreactivity, suggesting this as a probable site of action. Altogether, our observations support the idea that the cyclic nonapeptide (CP) derived from AFP, could represent a novel breast cancer therapeutic agent whose mechanism of action is different from that of drugs like tamoxifen and aromatase inhibitors (33).

Acknowledgements
This study was supported by Grant Nr 1040881 from Fondecyt Chile.

References